Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer

Southwest Oncology Group 9713

Martin J. Edelman, Kari Chansky, Laurie E. Gaspar, Bryan Leigh, Geoffrey R. Weiss, Sarah A. Taylor, John Crowley, Robert Livingston, David R Gandara

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Purpose: Limited small-cell lung cancer (LSCLC) is characterized by a high initial response rate to chemoradiotherapy, but local or systemic relapse occurs in the majority of patients. Previous Southwest Oncology Group trials in LSCLC have utilized cisplatin and etoposide (PE) delivered concurrently with thoracic radiotherapy followed by two consolidation cycles. Newer chemotherapy regimens such as paclitaxel and carboplatin are active in small-cell lung cancer and hold the promise of improving both local and systemic control. S9713 evaluated the substitution of paclitaxel and carboplatin for PE consolidation in LSCLC. Patients and Methods: Between July 1998 and August 1999, 96 patients were accrued from 43 institutions. Eighty-nine patients were eligible; 87 were assessable for survival and response. Treatment consisted of cisplatin 50 mg/m2 on days 1, 8, 29, and 36, and etoposide 50 mg/m2 on days 1 to 5 and days 29 to 33, with concurrent radiotherapy of 61 Gy beginning on day 1. Consolidation therapy was carboplatin (area under the curve = 6) and paclitaxel 200 mg/m2, both drugs administered on day 1 of a 21 day cycle for three cycles. Results: The response rate was 86% (complete response, 33%; partial response, 53%). Median overall survival was 17 months (95% CI, 12.7 to 19.0). One- and 2-year overall survivals were 61% and 33%, respectively. Median progression-free survival (PFS) was 9 months, 1-year PFS was 40%, and 2-year PFS was 21%. Conclusion: Consolidation therapy with paclitaxel and carboplatin in LSCLC resulted in an outcome similar to that seen in prior Southwest Oncology Group trials. This study and others which have tested paclitaxel in small-cell lung cancer dampens enthusiasm for this agent in the primary management of LSCLC.

Original languageEnglish (US)
Pages (from-to)127-132
Number of pages6
JournalJournal of Clinical Oncology
Volume22
Issue number1
DOIs
StatePublished - 2004
Externally publishedYes

Fingerprint

Carboplatin
Small Cell Lung Carcinoma
Etoposide
Paclitaxel
Cisplatin
Radiotherapy
Disease-Free Survival
Survival
Chemoradiotherapy
Area Under Curve
Thorax
Therapeutics
Recurrence
Drug Therapy
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer : Southwest Oncology Group 9713. / Edelman, Martin J.; Chansky, Kari; Gaspar, Laurie E.; Leigh, Bryan; Weiss, Geoffrey R.; Taylor, Sarah A.; Crowley, John; Livingston, Robert; Gandara, David R.

In: Journal of Clinical Oncology, Vol. 22, No. 1, 2004, p. 127-132.

Research output: Contribution to journalArticle

Edelman, Martin J. ; Chansky, Kari ; Gaspar, Laurie E. ; Leigh, Bryan ; Weiss, Geoffrey R. ; Taylor, Sarah A. ; Crowley, John ; Livingston, Robert ; Gandara, David R. / Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer : Southwest Oncology Group 9713. In: Journal of Clinical Oncology. 2004 ; Vol. 22, No. 1. pp. 127-132.
@article{181d06740a8e4d1bb70c99969af80183,
title = "Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713",
abstract = "Purpose: Limited small-cell lung cancer (LSCLC) is characterized by a high initial response rate to chemoradiotherapy, but local or systemic relapse occurs in the majority of patients. Previous Southwest Oncology Group trials in LSCLC have utilized cisplatin and etoposide (PE) delivered concurrently with thoracic radiotherapy followed by two consolidation cycles. Newer chemotherapy regimens such as paclitaxel and carboplatin are active in small-cell lung cancer and hold the promise of improving both local and systemic control. S9713 evaluated the substitution of paclitaxel and carboplatin for PE consolidation in LSCLC. Patients and Methods: Between July 1998 and August 1999, 96 patients were accrued from 43 institutions. Eighty-nine patients were eligible; 87 were assessable for survival and response. Treatment consisted of cisplatin 50 mg/m2 on days 1, 8, 29, and 36, and etoposide 50 mg/m2 on days 1 to 5 and days 29 to 33, with concurrent radiotherapy of 61 Gy beginning on day 1. Consolidation therapy was carboplatin (area under the curve = 6) and paclitaxel 200 mg/m2, both drugs administered on day 1 of a 21 day cycle for three cycles. Results: The response rate was 86{\%} (complete response, 33{\%}; partial response, 53{\%}). Median overall survival was 17 months (95{\%} CI, 12.7 to 19.0). One- and 2-year overall survivals were 61{\%} and 33{\%}, respectively. Median progression-free survival (PFS) was 9 months, 1-year PFS was 40{\%}, and 2-year PFS was 21{\%}. Conclusion: Consolidation therapy with paclitaxel and carboplatin in LSCLC resulted in an outcome similar to that seen in prior Southwest Oncology Group trials. This study and others which have tested paclitaxel in small-cell lung cancer dampens enthusiasm for this agent in the primary management of LSCLC.",
author = "Edelman, {Martin J.} and Kari Chansky and Gaspar, {Laurie E.} and Bryan Leigh and Weiss, {Geoffrey R.} and Taylor, {Sarah A.} and John Crowley and Robert Livingston and Gandara, {David R}",
year = "2004",
doi = "10.1200/JCO.2004.06.070",
language = "English (US)",
volume = "22",
pages = "127--132",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "1",

}

TY - JOUR

T1 - Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer

T2 - Southwest Oncology Group 9713

AU - Edelman, Martin J.

AU - Chansky, Kari

AU - Gaspar, Laurie E.

AU - Leigh, Bryan

AU - Weiss, Geoffrey R.

AU - Taylor, Sarah A.

AU - Crowley, John

AU - Livingston, Robert

AU - Gandara, David R

PY - 2004

Y1 - 2004

N2 - Purpose: Limited small-cell lung cancer (LSCLC) is characterized by a high initial response rate to chemoradiotherapy, but local or systemic relapse occurs in the majority of patients. Previous Southwest Oncology Group trials in LSCLC have utilized cisplatin and etoposide (PE) delivered concurrently with thoracic radiotherapy followed by two consolidation cycles. Newer chemotherapy regimens such as paclitaxel and carboplatin are active in small-cell lung cancer and hold the promise of improving both local and systemic control. S9713 evaluated the substitution of paclitaxel and carboplatin for PE consolidation in LSCLC. Patients and Methods: Between July 1998 and August 1999, 96 patients were accrued from 43 institutions. Eighty-nine patients were eligible; 87 were assessable for survival and response. Treatment consisted of cisplatin 50 mg/m2 on days 1, 8, 29, and 36, and etoposide 50 mg/m2 on days 1 to 5 and days 29 to 33, with concurrent radiotherapy of 61 Gy beginning on day 1. Consolidation therapy was carboplatin (area under the curve = 6) and paclitaxel 200 mg/m2, both drugs administered on day 1 of a 21 day cycle for three cycles. Results: The response rate was 86% (complete response, 33%; partial response, 53%). Median overall survival was 17 months (95% CI, 12.7 to 19.0). One- and 2-year overall survivals were 61% and 33%, respectively. Median progression-free survival (PFS) was 9 months, 1-year PFS was 40%, and 2-year PFS was 21%. Conclusion: Consolidation therapy with paclitaxel and carboplatin in LSCLC resulted in an outcome similar to that seen in prior Southwest Oncology Group trials. This study and others which have tested paclitaxel in small-cell lung cancer dampens enthusiasm for this agent in the primary management of LSCLC.

AB - Purpose: Limited small-cell lung cancer (LSCLC) is characterized by a high initial response rate to chemoradiotherapy, but local or systemic relapse occurs in the majority of patients. Previous Southwest Oncology Group trials in LSCLC have utilized cisplatin and etoposide (PE) delivered concurrently with thoracic radiotherapy followed by two consolidation cycles. Newer chemotherapy regimens such as paclitaxel and carboplatin are active in small-cell lung cancer and hold the promise of improving both local and systemic control. S9713 evaluated the substitution of paclitaxel and carboplatin for PE consolidation in LSCLC. Patients and Methods: Between July 1998 and August 1999, 96 patients were accrued from 43 institutions. Eighty-nine patients were eligible; 87 were assessable for survival and response. Treatment consisted of cisplatin 50 mg/m2 on days 1, 8, 29, and 36, and etoposide 50 mg/m2 on days 1 to 5 and days 29 to 33, with concurrent radiotherapy of 61 Gy beginning on day 1. Consolidation therapy was carboplatin (area under the curve = 6) and paclitaxel 200 mg/m2, both drugs administered on day 1 of a 21 day cycle for three cycles. Results: The response rate was 86% (complete response, 33%; partial response, 53%). Median overall survival was 17 months (95% CI, 12.7 to 19.0). One- and 2-year overall survivals were 61% and 33%, respectively. Median progression-free survival (PFS) was 9 months, 1-year PFS was 40%, and 2-year PFS was 21%. Conclusion: Consolidation therapy with paclitaxel and carboplatin in LSCLC resulted in an outcome similar to that seen in prior Southwest Oncology Group trials. This study and others which have tested paclitaxel in small-cell lung cancer dampens enthusiasm for this agent in the primary management of LSCLC.

UR - http://www.scopus.com/inward/record.url?scp=4143093239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4143093239&partnerID=8YFLogxK

U2 - 10.1200/JCO.2004.06.070

DO - 10.1200/JCO.2004.06.070

M3 - Article

VL - 22

SP - 127

EP - 132

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 1

ER -